AbCellera today announced new data on its PSMA x CD3 T-cell engagers, presented as a poster at the American Association for Cancer ResearchⓇ 116th Annual Meeting at the McCormick Place Convention ...

Candid, which is making bispecifics for immune diseases, has also raised $505 million in a private financing for the newly formed company.

SAN DIEGO and SUZHOU, China and SPRING HOUSE, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (ADAG) and Third Arc Bio, Inc. (“Third Arc Bio”), today announced a licensing agreement under which ...

SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel ...

Astellas Pharma Inc. and Vir Biotechnology, Inc. have entered into a global strategic collaboration to advance VIR-5500, an ...

Cullinan Therapeutics (NASDAQ:CGEM) executives highlighted multiple upcoming catalysts across the company’s oncology and autoimmune portfolio during a presentation at Citi’s Virtual Oncology ...

Explore the evolution of T-cell engagers, from experimental concepts to effective therapies for haematologic malignancies.

Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), today announced ...

Preclinical data on AbCellera’s PSMA x CD3 T-cell engagers demonstrate potent anti-tumor activity and potential to further enhance function through costimulatory strategies Targeting prostate-specific ...